Triplet Regimens Are New Frontier for AML Therapy
Triplet therapy regimens now are on the horizon for patients with AML, thanks to ongoing research into targeted therapies.
Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?
Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
Potential Need to Update Recommendations for CNS Prophylaxis in ALL
With the emergence of tyrosine kinase inhibitors and targeted immunotherapies in the front line, outcomes for patients with ALL have improved. However, questions about central nervous system involvement and prophylaxis persist.
Quizartinib Becomes SOC Option in Newly Diagnosed AML With FLT3 ITD Mutation
Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.
Should Patients With Smoldering Myeloma Be Treated or Observed?
At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.
MRD-Negative Complete Remission in Ph+ ALL Boosts With Ponatinib
Addition of ponatinib led to a higher rate of MRD-negative complete remission vs imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Investigation of AYA Ph- ALL Outcomes With Pediatric-Inspired Regimens Needed
Further investigation into the outcomes of adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia when treated with pediatric-inspired regimens are warranted.
Oncology Icons: Recognizing Key Innovators in Community Oncology Research
Targeted Oncology recently honored 3 outstanding oncologists who have been influential in the community oncology space for years.
Cilta-Cel Reduces Risk of Disease Progression in RRMM
In an interview with Targeted Oncology, Binod Dhakal, MD, discussed results from the phase 3 CARTITUDE-4 study of cilta-cel in patients with lenalidomide-refractory multiple myeloma.
Amivantamab Plus Chemo Extends PFS in Advanced EGFR-Mutated NSCLC
The phase 3 MARIPOSA-2 study has met its primary end point.
Fostrox Plus Lenvatinib Shows Encouraging Results in HCC
Interim analysis results from a study of fostroxacitabine bralpamide plus lenvatinib show positive preliminary efficacy and safety.
Longer Follow-Up BRUIN Data Continues to Support Pirtobrutinib in MCL
In an interview with Targeted Oncology, Nirav Shah, MD, discussed long-term follow-up results from the phase 1/2 BRUIN study and how the approval of pirtobrutinib has changed the MCL treatment landscape.
CHRYSALIS Study Shows Potential of Amivantamab/Lazertinib in EGFRm NSCLC
Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Tisotumab Vedotin Achieves a Statistically Significant OS Improvement in Advanced Cervical Cancer
Further data support the recent accelerated FDA approval of tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Phase 2 of ARROS-1 Trial Assessing NVL-520 in Solid Tumors Commences
As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.
Promising Research to Advance Treatment of Gastrointestinal Stromal Tumors
In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.
Trials Investigate Sacituzumab as Earlier Treatment for Breast Cancer
Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.
Pembrolizumab Added to Chemotherapy Improves PFS in Endometrial Cancer
Regardless of mismatch repair status, the phase 3 NRG-GY018 trial showed an improvement in progression-free survival when patients with endometrial cancer were given pembrolizumab with chemotherapy.
Bintrafusp Alfa Shows Similar Efficacy to Pembrolizumab in PD-L1-High/Advanced NSCLC
No significant difference in efficacy outcomes were shown with bintrafusp alfa vs pembrolizumab in patients with PD-L1-high, advanced non–small cell lung cancer. However, further investigation may offer more information about the benefit of this drug class.
ALINA Study of Alectinib Meets Primary DFS End Point in ALK+ NSCLC
Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Garg Breaks Down the Treatment Landscape in Endometrial Cancer
In an interview with Targeted Oncology, Ruchi Garg, MD, discussed the evolution of the treatment landscape for patients with endometrial cancer and what trials to watch out for in the future.
First Patient With mCRPC Receives Highest Dose of Novel PSMA Theranostic
Following positive results from cohorts 1 and 2 of the SECuRE trial, dosing of 64Cu/67Cu SAR-bisPSMA has begun in patients with metastatic castration-resistant prostate cancer in cohort 3.
FDA Grants Multiple Breakthrough Therapy Designations to Trastuzumab Deruxtecan
Fam-trastuzumab deruxtecan-nxki was granted 2 breakthrough therapy designations by the FDA for its potential to fill a treatment gap for HER2-expressing tumors.
City of Hope is First to Offer a Novel Precision Medicine Technology in Southern California
RefleXion X1 is now being used at City of Hope Comprehensive Cancer Center.
Ovarian Cancer Trials Expand Research Across Subtypes
In an interview Targeted Oncology, Christina Fotopoulou, MD, PhD, discussed the background and results of 3 studies for patients with ovarian cancer.
Oncologists Call for Legislative Action to Address US Drug Shortages
Amid the ongoing chemotherapy drug shortage in the United States, experts like Nathan Bahary, MD, and Anne LaCasce, MD, MMSc, push for the passing of legislation, yet keep their patients their top priority.
Bexmarilimab Gains FDA Orphan Drug Designation for AML
The phase 1/2 BEXMAB study is investigating the combination of bexmarilimab with standard of care in patients with hematologic malignancies.
Ending IO at 2 Years May Be Reasonable for Patients With NSCLC
A retrospective study found no additional benefit for patients with non–small cell lung cancer who continued immunotherapy beyond 2 years.
sNDA Submitted to the FDA for Erdafitinib in mUC
Promising overall survival findings from cohort 1 of the THOR study evaluating erdafitinib in locally advanced or metastatic urothelial cancer have pushed the agent’s developer to submit an sNDA seeking its full approval.
2 Clarke Drive Cranbury, NJ 08512